Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
MP McGinley, JA Cohen - The Lancet, 2021 - thelancet.com
Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy
C Bunschoten, BC Jacobs, PYK Van den Bergh… - The Lancet …, 2019 - thelancet.com
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and
heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are …
heterogeneous but treatable immune-mediated neuropathy. Nerve conduction studies are …
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy …
PYK Van den Bergh, PA van Doorn… - Journal of the …, 2021 - Wiley Online Library
To revise the 2010 consensus guideline on chronic inflammatory demyelinating
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and …
polyradiculoneuropathy (CIDP). Seventeen disease experts, a patient representative, and …
Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated
neuropathy typically characterised by symmetrical involvement, and proximal as well as …
neuropathy typically characterised by symmetrical involvement, and proximal as well as …
Immune-mediated neuropathies: pathophysiology and management
Dysfunction of the immune system can result in damage of the peripheral nervous system.
The immunological mechanisms, which include macrophage infiltration, inflammation and …
The immunological mechanisms, which include macrophage infiltration, inflammation and …
Novel immunological and therapeutic insights in Guillain-Barré syndrome and CIDP
L Querol, C Lleixà - Neurotherapeutics, 2021 - Springer
Inflammatory neuropathies are a heterogeneous group of rare diseases of the peripheral
nervous system that include acute and chronic diseases, such as Guillain-Barré syndrome …
nervous system that include acute and chronic diseases, such as Guillain-Barré syndrome …
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre …
JA Allen, J Lin, I Basta, T Dysgaard, C Eggers… - The Lancet …, 2024 - thelancet.com
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an
autoimmune disease of the peripheral nervous system that can lead to severe disability from …
autoimmune disease of the peripheral nervous system that can lead to severe disability from …
Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)
L Querol, M Crabtree, M Herepath, E Priedane… - Journal of …, 2021 - Springer
Background Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare
neurological disorder characterised by muscle weakness and impaired sensory function …
neurological disorder characterised by muscle weakness and impaired sensory function …
[HTML][HTML] The role of the complement system in chronic inflammatory demyelinating polyneuropathy: implications for complement-targeted therapies
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common,
heterogeneous, immune-mediated neuropathy, characterized by predominant …
heterogeneous, immune-mediated neuropathy, characterized by predominant …
[HTML][HTML] Update on intravenous immunoglobulin in neurology: modulating neuro-autoimmunity, evolving factors on efficacy and dosing and challenges on stopping …
MC Dalakas - Neurotherapeutics, 2021 - Elsevier
In the last 25 years, intravenous immunoglobulin (IVIg) has had a major impact in the
successful treatment of previously untreatable or poorly controlled autoimmune neurological …
successful treatment of previously untreatable or poorly controlled autoimmune neurological …